Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
CRANBURY, N.J., Sept 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Amicus Therapeutics Announces Second Quarter 2007 Financial Results Cranbury, NJ, August 2, 2007 - Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced
View HTML
Toggle Summary Amicus Therapeutics (FOLD) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
Company to Celebrate Initial Public Offering On NASDAQ
View HTML
Toggle Summary Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock
CRANBURY, N.J., May 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today the pricing of its initial public offering (IPO) of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.
View HTML
Toggle Summary Amicus Therapeutics Files For Initial Public Offering
Amicus Therapeutics Files For Initial Public Offering CRANBURY, N.J., Mar 30, 2007 /PRNewswire via COMTEX News Network/ -- CRANBURY, N.J., March 30 /PRNewswire/- Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC)
View HTML
Toggle Summary Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera(TM) for Gaucher Disease
Phase 2 Clinical Trials Initiated
View HTML
Toggle Summary AMICUS THERAPEUTICS PRESENTS PRECLINICAL DATA FROM STUDIES OF PLICERA
Studies Show Increased Enzyme Levels in Two Most Common Mutations
View HTML
Toggle Summary AMICUS THERAPEUTICS PRESENTS DATA FROM PRECLINICAL AND PHASE 1 STUDIES OF AMIGAL
Studies in Mice Show Reduction of Enzyme Substrate
View HTML
Toggle Summary AMICUS THERAPEUTICS COMPLETES PHASE 2 ENROLLMENT OF AMIGAL™ FOR FABRY DISEASE
AMICUS THERAPEUTICS COMPLETES PHASE 2 ENROLLMENT OF AMIGAL ™ FOR FABRY DISEASE Cranbury, NJ, March 16, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced
View HTML
Toggle Summary AMICUS THERAPEUTICS ANNOUNCES RETURN OF JOHN F. CROWLEY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
AMICUS THERAPEUTICS ANNOUNCES RETURN OF JOHN F. CROWLEY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER Cranbury, NJ, March 5, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human
View HTML